KIT mutations have been found in the rare subgroup of patients with mucosal melanoma, acral melanoma and melanoma arising on chronically sun damaged skin, which has raised the possibility of utilizing imatinib mesylate for targeted therapy in these types of melanoma. Here, KIT is linked to mucosal melanoma.